# Intercure Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Intercure Ltd.). ## Overview InterCure Ltd. is an Israel-based medical cannabis company operating through its Canndoc subsidiary, with cultivation, manufacturing, and distribution tied together in a vertically integrated seed-to-sale model. Its business centers on GMP-certified, pharmaceutical-grade cannabis products for regulated medical markets, including Israel and selected international markets. ## Products & services • GMP-certified medical cannabis products • Pharmaceutical-grade cannabis flower and extracts • Cultivation and processing of cannabis • Licensed distribution to medical channels • International market entry and partnerships - **Medical cannabis products** (70%) — Cannabis-based products sold for regulated medical use, including flower and related formats. - **Cultivation and processing** (20%) — Growing, harvesting, and preparing cannabis biomass for sale and distribution. - **Distribution and market access** (10%) — Licensed distribution services and channel access for medical cannabis products. - GMP-certified medical cannabis products - Pharmaceutical-grade cannabis flower and extracts - Cultivation and processing of cannabis - Licensed distribution to medical channels - International market entry and partnerships ## Customers InterCure sells primarily into regulated medical cannabis channels, where patients access products through licensed healthcare and dispensing systems. It also serves institutional and commercial partners in markets where product registration, importation, or local distribution partnerships are needed. - **Medical cannabis patients** (primary) — Patients buying physician-recommended cannabis products for regulated medical use. - **Pharmacies and dispensaries** (primary) — Licensed outlets that dispense InterCure/Canndoc products to end patients. - **International channel partners** (secondary) — Partners that import, register, or distribute products in foreign medical markets. - **Regulated U.S. medical markets** (emerging) — Potential market access for regulated medical cannabis opportunities only. - Medical cannabis patients using regulated dispensing channels - Licensed pharmacies and dispensaries - Healthcare-facing distribution partners - International partners in regulated medical markets - Regulatory-compliant channel partners in new markets ## Geography InterCure is headquartered in Israel and is anchored by its domestic cannabis operations there, while also building exposure to Germany and other regulated international medical markets. The company has highlighted expansion activity in Europe and a selective review of U.S. opportunities limited to regulated medical cannabis markets. - **Israel** — Core operating base and historical revenue center - **Germany** — Early international medical cannabis market - **Other international markets** — Regulated markets outside Israel and Germany - Israel is the core operating base and main production center - Germany is an important international growth market - Europe is the main expansion region outside Israel - U.S. opportunities are limited to regulated medical markets - Geography matters because cannabis is highly regulated by country ## Strategy InterCure’s strategy is to build a multi-country medical cannabis platform by combining domestic strength in Israel with selective expansion into large regulated European markets. It also emphasizes partnerships, product launches, and acquisitions or investments that broaden its research, cultivation, and distribution capabilities. - **International expansion in regulated markets** (medium-term) — Diversifies the business beyond Israel and targets larger addressable markets. - **Product launch pipeline** (short-term) — New formulations and registrations support channel growth and shelf presence. - **Vertical integration** (long-term) — Control over cultivation, processing, and distribution supports quality and channel control. - **Research and collaboration capability** (medium-term) — R&D partnerships can improve product development and market differentiation. - Expand in Germany and other regulated European markets - Use partnerships to speed market entry and product launches - Leverage vertically integrated cultivation and distribution - Pursue selective U.S. opportunities in regulated medical markets - Add research capability through strategic investments ## Risks InterCure faces regulatory, market-access, and execution risks that are common to cannabis operators, especially because each market depends on local licensing and product approvals. It also has exposure to geopolitical and operational disruption in Israel, while international growth depends on winning distribution, navigating import rules, and sustaining product quality. - **Regulatory dependence** [high] — Medical cannabis sales depend on licenses, product registrations, and local rules in each market. - **Geopolitical disruption in Israel** [high] — Core cultivation and management functions are tied to Israel, creating operational disruption risk. - **Execution risk in international expansion** [high] — Growth in Germany and elsewhere requires product launches, local partners, and regulatory approvals. - **Cannabis market pricing pressure** [medium] — Medical cannabis markets can see rapid changes in supply, competition, and pricing. - **Quality and compliance risk** [medium] — GMP and pharmaceutical-grade positioning require consistent standards across production and distribution. - Cannabis regulation can change market access and product approvals - Israel-based operations face geopolitical and operating disruption risk - International growth depends on local licenses and distributor execution - Product quality or GMP issues could hurt trust and registrations - Cannabis demand and pricing can be volatile across markets ## Accounting InterCure’s reported results are affected by fair-value measurement of inventory and by estimates tied to credit risk, impairment, and compensation-related items. As a cannabis company with vertically integrated production and international expansion, revenue timing, inventory valuation, and any impairment or fair-value adjustments can materially affect period-to-period comparability. - **Inventory fair value and impairment** — Affects gross profit and operating results - **Allowance for credit risk** — Affects earnings and balance sheet quality - **Non-IFRS Adjusted EBITDA adjustments** — Can materially change the bridge from net income to operating performance - **Quarterly revenue timing** — Affects comparability across quarters - Fair value changes in inventory can move operating results - Credit-loss allowances affect receivables and earnings - Inventory impairment matters in a regulated, perishable product business - Non-IFRS Adjusted EBITDA excludes several recurring adjustments - Quarterly comparability can shift with product launches and market timing --- *Last updated: 2026-09-28T12:04:07.456224+00:00*